[1]徐彬,蒋立虹.可溶性鸟苷酸环化酶激动剂的安全性探究[J].国际心血管病杂志,2024,03:171-174.
点击复制
可溶性鸟苷酸环化酶激动剂的安全性探究(PDF)
《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]
- 期数:
- 2024年03期
- 页码:
- 171-174
- 栏目:
- 综述
- 出版日期:
- 2024-05-20
文章信息/Info
- Title:
- -
- Author(s):
- -
- 关键词:
- 心力衰竭; 可溶性鸟苷酸环化酶激动剂; 维利西呱; 安全性
- Keywords:
- -
- 分类号:
- -
- DOI:
- 10.3969/j.issn.1673-6583.2024.03.012
- 文献标识码:
- -
- 摘要:
- 维利西呱是新型的口服可溶性鸟苷酸环化酶激动剂，通过重建一氧化氮- 可溶 性鸟苷酸环化酶- 环磷酸鸟苷（NO-sGC-cGMP）信号通路，改善心肌和血管功能，为心力衰 竭的治疗提供新思路。该文介绍目前开展的维利西呱临床试验，旨在对其应用安全性提供相 关证据支持。
- Abstract:
- -
参考文献/References
[1] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/
HFSA guideline for the management of heart failure: executive
summary: a report of the American College of Cardiology/
American Heart Association Joint Committee on clinical practice
guidelines[J]. Circulation, 2022, 145(18):e876-e894.
[2] Roger VL. Epidemiology of heart failure: a contemporary
perspective[J]. Circ Res, 2021, 128(10):1421-1434.
[3] Savarese G, Becher PM, Lund LH, et al. Global burden of heart
failure: a comprehensive and updated review of epidemiology[J].
Cardiovasc Res, 2023, 118(17):3272-3287.
[4] Williams DM, Evans M. Are SGLT-2 inhibitors the future of heart
failure treatment? The EMPEROR-Preserved and EMPERORReduced
trials[J]. Diabetes Therapy, 2020, 11(9):1925-1934.
[5] Hao G, Wang X, Chen Z, et al. Prevalence of heart failure and
left ventricular dysfunction in China: the China Hypertension
Survey, 2012-2015[J]. Eur J Heart Fail, 2019, 21(11):1329-1337.
[6] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines
for the diagnosis and treatment of acute and chronic heart
failure[J]. Eur Heart J, 2021, 42(36):3599-3726.
[7] 中国老年医学学会心电及心功能分会, 中国医师协会心血管
内科分会, 中国心衰中心联盟专家委员会. 慢性心力衰竭加重
患者的综合管理中国专家共识2022[J]. 中国循环杂志, 2022,
37(3):215-225.
[8] Farah C, Michel LYM, Balligand JL. Nitric oxide signalling in
cardiovascular health and disease[J]. Nat Rev Cardiol, 2018,
15(5):292-316.
[9] Kaplinsky E, Perrone S, Barbagelata A. Emerging concepts in
heart failure management and treatment: focus on vericiguat[J].
Drugs Context, 2023, 12:2022-5-5.
[10] Friebe A, Sandner P, Schmidtko A. cGMP: a unique 2nd
messenger molecule—recent developments in cGMP research
and development[J]. Naunyn Schmiedebergs Arch Pharmacol,
2020, 393(2):287-302.
[11] Gambaryan S. The role of NO/sGC/cGMP/PKG signaling
pathway in regulation of platelet function[J]. Cells, 2022,
11(22):3704.
[12] Greenberg B. Medical management of patients with heart failure
and reduced ejection fraction[J]. Korean Circ J, 2022, 52(3):173-
197.
[13] Coats AJS, Tolppanen H. Drug treatment of heart failure with
reduced ejection fraction: defining the role of vericiguat[J].
Drugs, 2021, 81(14):1599-1604.
[14] Tran BA, Serag-Bolos ES, Fernandez J, et al. Vericiguat: the
first soluble guanylate cyclase stimulator for reduction of
cardiovascular death and heart failure hospitalization in patients
with heart failure reduced ejection fraction[J]. J Pharm Pract,
2023, 36(4):905-914.
[15] Vannuccini F, Campora A, Barilli M, et al. Vericiguat in heart
failure: characteristics, scientific evidence and potential clinical
applications[J]. Biomedicines, 2022, 10(10):2471.
[16] Scrutinio D, Di Lenarda A, Cherubini A. The SOCRATESREDUCED
study[J]. G Ital Cardiol (Rome), 2017, 18(2):81-86.
[17] Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in
patients with heart failure and reduced ejection fraction[J]. N
Engl J Med, 2020, 382(20):1883-1893.
[18] Mentz RJ, Stebbins A, Butler J, et al. Recurrent hospitalizations
and response to vericiguat in heart failure and reduced ejection
fraction[J]. JACC Heart Fail, 2024, S2213-1779(23):00840-5.
[19] Pieske B, Patel MJ, Westerhout CM, et al. Baseline features of
the VICTORIA (Vericiguat Global Study in Subjects with Heart
Failure with Reduced Ejection Fraction) trial[J]. Eur J Heart Fail,
2019, 21(12):1596-1604.
[20] Armstrong PW, Zheng Y, Troughton RW, et al. Sequential
evaluation of NT-proBNP in heart failure: insights into clinical
outcomes and efficacy of vericiguat[J]. JACC Heart Fail, 2023,
10(9):677-688.
[21] Senni MCE, Alemayehu WG, Sim D, et al. Efficacy and safety
of vericiguat in patients with heart failure with reduced ejection
fraction treated with sacubitril/valsartan: insights from the
VICTORIA trial[J]. Eur J Heart Fail, 2022, 24(9):1614-1622.
[22] Voors AA, Mulder H, Reyes E, et al. Renal function and the
effects of vericiguat in patients with worsening heart failure
with reduced ejection fraction: insights from the VICTORIA
(Vericiguat Global Study in Subjects with HFrEF) trial[J]. Eur J
Heart Fail, 2021, 23(8):1313-1321.
[23] 张荣成, 赵雪梅, 张宇辉, 等. 心力衰竭患者血钾水平与室性心
律失常及住院死亡的关系[J]. 中国循环杂志, 2020, 35(4):361-
367．
[24] Hoss S, Elizur Y, Luria D, et al. Serum Potassium levels and
outcome in patients with chronic heart failure[J]. Am J Cardiol,
2016, 118(12):1868-1874.
[25] Krogager ML, Eggers-Kaas L, Aasbjerg K, et al. Short-term
mortality risk of serum potassium levels in acute heart failure
following myocardial infarction[J]. Eur Heart J Cardiovasc Pharmacother, 2015, 1(4):245-251.
[26] Glantzounis GK, Tsimoyiannis EC, Kappas AM, et al. Uric acid
and oxidative stress[J]. Curr Pharm Des, 2005, 11(32):4145-
4151.
[27] Kramer F, Voss S, Roessig L, et al. Evaluation of high-sensitivity
C-reactive protein and uric acid in vericiguat-treated patients
with heart failure with reduced ejection fraction[J]. Eur J Heart
Fail, 2020, 22(9):1675-1683.
[28] Ponikowski P, Alemayehu W, Oto A, et al. Vericiguat in patients
with atrial fibrillation and heart failure with reduced ejection
fraction: insights from the Victoria trial[J]. Eur J Heart Fail,
2021, 23(8):1300-1312.
[29] Abuelazm MT, Attia A, Abdelnabi M, et al. Soluble guanylate
cyclase stimulators for heart failure: a network meta-analysis and
subgroup analyses of reduced and preserved ejection fraction[J].
Egypt Heart J, 2024, 76(1):6.
[30] Dies RM, Jackson CN, Flanagan CJ, et al. The evolving role of
vericiguat in patients with chronic heart failure[J]. Cureus, 2023,
15(12):e49782.
备注/Memo
- 备注/Memo:
-
基金项目：国家自然科学基金（81960068）；云南省特色中药创新
应用重点实验室（202205AG070005）
通信作者：蒋立虹， E-mail：jlh15198763375@163.com
常用功能
统计/Statistics
- 摘要浏览/Viewed147
- 全文下载/Downloads172
- 评论/Comments
